CRISPR Therapeutics AG
CRSP
$53.52
$1.883.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,041.37% | 68.55% | -97.58% | 47.67% | 72.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,041.37% | 68.55% | -97.58% | 47.67% | 72.53% |
| Cost of Revenue | -6.63% | -11.90% | 67.04% | 24.33% | -13.04% |
| Gross Profit | 14.81% | 12.44% | -193.49% | -24.18% | 13.37% |
| SG&A Expenses | -7.21% | -10.95% | 1.52% | -2.80% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.71% | -11.78% | 55.20% | 20.06% | -11.74% |
| Operating Income | 13.73% | 12.25% | -139.62% | -19.91% | 12.02% |
| Income Before Tax | 56.48% | 9.49% | -255.08% | -24.40% | -65.65% |
| Income Tax Expenses | -25.70% | -24.35% | -12.29% | -29.34% | 0.39% |
| Earnings from Continuing Operations | 56.29% | 9.61% | -250.07% | -23.85% | -64.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.29% | 9.61% | -250.07% | -23.85% | -64.98% |
| EBIT | 13.73% | 12.25% | -139.62% | -19.91% | 12.02% |
| EBITDA | 13.94% | 12.36% | -149.56% | -21.10% | 12.29% |
| EPS Basic | 60.57% | 19.13% | -214.02% | -15.62% | -60.91% |
| Normalized Basic EPS | 28.70% | 19.02% | -218.57% | -16.13% | 13.48% |
| EPS Diluted | 60.65% | 19.12% | -214.04% | -15.84% | -61.07% |
| Normalized Diluted EPS | 28.70% | 19.02% | -218.57% | -16.13% | 13.48% |
| Average Basic Shares Outstanding | 10.85% | 11.77% | 11.47% | 7.12% | 2.53% |
| Average Diluted Shares Outstanding | 10.85% | 11.77% | 11.47% | 7.12% | 2.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |